Natera, Inc. (NTRA) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 7:30 PM EST
Company Participants
Steve Chapman – CEO & Director
Alexey Aleshin – GM of Oncology and ECD & Chief Medical Officer
Solomon Moshkevich – President of Clinical Diagnostics
Mike Brophy – Chief Financial Officer
Conference Call Participants
Casey Woodring – JPMorgan Chase & Co, Research Division
Presentation
Casey Woodring
JPMorgan Chase & Co, Research Division
All right. Great. Looks like we can get started here. Hi, everybody. Welcome to JPMorgan Healthcare Conference. My name is Casey Woodring from Life Science Tools and Diagnostics team. Pleased to be joined by the management team of Natera. The company will go through their corporate presentation, then we’ll do the Q&A session afterwards. So with that, I’ll pass it to Steve.
Steve Chapman
CEO & Director
Yes. Great. Thanks for having us. This is the standard safe harbor. So the mission of Natera is transforming the management of disease worldwide. And we do that with a proprietary technology that can detect extremely tiny quantities of DNA that combines molecular techniques with bioinformatics techniques that were developed at Natera. We first applied this technology in cell-free DNA in 2013 with Panorama, which is a cell-free fetal DNA test that looks at chromosomal abnormalities.
We were the fourth company to launch in a very competitive market. But today, we are, by far, the market leader with more than 50% market share. We took that same technology, and we applied that in the field of organ health, where we look at donor-derived cell-free DNA in the setting of an organ transplant to identify rejection non-invasively, a product there is called Prospera. And then, of course, in the field of oncology, where we look at circulating tumor DNA in the setting of minimal residual disease or recurrence monitoring and our product there is Signatera.
